Skip to main content
. 2013 Jul;27(7):393–396. doi: 10.1155/2013/170546

TABLE 4.

Survival and treatment outcomes of patients treated with sorafenib

Sorafenib dose/day
P
800 mg (n=33) 400 mg (n=66)
Overall survival, months, mean 7.8 7.1 0.14
Three-month radiological response (tumour burden)
  Stable 6 (18) 13 (20) 1.0
  Increased 18 (55) 30 (45) 0.4
  Decreased 1 (3) 4 (6) 0.6
  Unknown 8 (24) 19 (29) 0.8
Disease control rate 7 (21) 17 (26) 0.8
Three-month alpha-fetoprotein levels
  Stable 5 (15) 8 (12) 0.7
  Increased 12 (37) 25 (38) 1.0
  Decreased 1 (3) 10 (15) 0.09
  Unknown 15 (45) 23 (35) 0.4

Data presented as n (%) unless otherwise indicated